AVANIR Pharmaceuticals Presents Data At American Neurological Association Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced the presentation of two posters at the American Neurological Association’s 133rd Annual Meeting in Salt Lake City. The posters covered the results of the pharmacokinetic/pharmacodynamic (PK/PD) modeling that was used to predict the safety and efficacy of the new lower dose formulation of Zenvia™ (dextromethorphan/quinidine [DM/Q]) now being tested in the ongoing STAR Phase III trial, as well as the impact of pseudobulbar affect (PBA) on caregivers.